ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Anova Innovation Limited
Anova Innovation Limited
ImmunityBio, Inc.
Bristol-Myers Squibb
Genmab
Lumos Pharma
Verastem, Inc.
Revolution Medicines, Inc.
UNC Lineberger Comprehensive Cancer Center
iOnctura
Washington University School of Medicine
Tongji Hospital
Artios Pharma Ltd
Institut du Cancer de Montpellier - Val d'Aurelle
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Akeso
University of Maryland, Baltimore
Engeneic Pty Limited
Lokon Pharma AB
M.D. Anderson Cancer Center
Shanghai Hengrui Pharmaceutical Co., Ltd.
Ascentage Pharma Group Inc.
University of Michigan Rogel Cancer Center
Suzhou Transcenta Therapeutics Co., Ltd.
Oncolytics Biotech
University Health Network, Toronto
Genfleet Therapeutics (Shanghai) Inc.
Hoffmann-La Roche
Servier
Thomas Jefferson University
Phanes Therapeutics
Incyte Corporation
Bristol-Myers Squibb
Ability Pharmaceuticals SL
GWT-TUD GmbH
Verastem, Inc.
Incyte Corporation
Lisata Therapeutics, Inc.
Prestige Biopharma Limited
NGM Biopharmaceuticals, Inc
Precision Biologics, Inc
Zhejiang University
Esperas Pharma Inc.
InxMed (Shanghai) Co., Ltd.
Zhejiang University
Herlev Hospital
BeyondBio Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chinese PLA General Hospital
Nelum Corp
Cyteir Therapeutics, Inc.